Rodman & Renshaw
http://www.rodmanandrenshaw.com/Rodman & Renshaw is an investment bank. The firm provides investment banking services to companies that have significant recurring capital needs along with research, sales, and trading services to institutional investors. The firm focuses on the biotechnology sector and since 2003 has been a leading investment bank to the sector. The firm is also a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
View Older Stories
-
Rodman & Renshaw Starts TuHURA Biosciences (HURA) at Buy
-
Rodman & Renshaw Starts CAMP4 Therapeutics Corp (CAMP) at Buy
-
Rodman & Renshaw Starts SAB Biotherapeutics (SABS) at Buy
-
Rodman & Renshaw Starts BioXcel Therapeutics (BTAI) at Buy, PT $17
-
Rodman & Renshaw Starts Karyopharm Therapeutics (KPTI) at Buy, PT $28
-
Rodman & Renshaw Starts Elicio Therapeutics (ELTX) at Buy
-
Soligenix enters agreement to sell up to $3.45 million in stock
-
Rodman & Renshaw Starts Beyond Air (XAIR) at Buy
-
Rodman & Renshaw Starts Telomir Pharma (TELO) at Buy
-
Rodman & Renshaw Starts Ascentage Pharma Group (AAPG) at Buy
-
Rodman & Renshaw Starts Biomea Fusion Inc. (BMEA) at Buy
-
Rodman & Renshaw Starts BioAtla Inc. (BCAB) at Buy
-
Rodman & Renshaw Starts Jasper Therapeutics (JSPR) at Buy
-
Scilex raises $20.3 million through warrant exercise
-
Scilex raises $20.3 million through warrant exercise agreement
-
Fitell secures $50 million convertible note financing for robotics venture
-
MIRA Pharmaceuticals sells 1.75M shares at 66% premium
-
Bluejay Diagnostics closes $4.5 million private placement
-
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Bluejay Diagnostics raises $4.5 million in private placement
-
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
-
Fitell launches $100M Solana treasury strategy with DeFi focus
-
Actelis Networks raises $1.6 million through warrant exercise
-
Banzai International (BNZI) Secures $11M in Debt Financing
-
Kairos Pharma (KAPA) Issues Letter to Stockholders
-
Kairos Pharma Ltd. Provides Letter to Stockholders
-
Rodman & Renshaw Reiterates Buy Rating on CorMedix (CRMD), PT $20, 'weakness today is likely overdone'
-
Rodman & Renshaw Reiterates Sell Rating on Cassava Sciences (SAVA), PT $2
-
Trevi Therapeutics (TRVI) PT Raised to $20 at Rodman & Renshaw
-
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
-
Rodman & Renshaw Reiterates Buy Rating on Adial Pharmaceuticals Inc (ADIL)
-
BioXcel Therapeutics (BTAI) announces direct offering of $14 million
-
Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
Rodman & Renshaw Starts Telomir Pharma (TELO) at Buy
-
Fitell Corporation (FTEL) Announces Updated Registered Direct Offering for up to $10.0 Million
-
Fitell Corporation (FTEL) Announces $10.0 Million Registered Direct Offering
-
GH Research PLC (GHRS) PT Raised to $42 at Rodman & Renshaw
-
Rodman & Renshaw Starts Cardiol Therapeutics (CRDL) at Buy
-
Rodman & Renshaw Starts Indivior (INDV) at Buy
-
Rodman & Renshaw Starts Rein Therapeutics (RNTX) at Buy
-
Rodman & Renshaw Starts PolyPid Ltd. (PYPD) at Buy
-
Rodman & Renshaw Starts Talphera (TLPH) at Buy
-
Rodman & Renshaw Starts INmune Bio Inc. (INMB) at Buy
-
Compass Pathways (CMPS) PT Lowered to $9 at Rodman & Renshaw
-
Kairos Pharma (KAPA) Provides Business Update and Outlook into 2025
-
Kairos Pharma Provides Business Update and Outlook into 2025
-
Rodman & Renshaw Starts Atara Biotherapeutics (ATRA) at Buy
-
Rodman & Renshaw Starts TuHURA Biosciences (HURA) at Buy
-
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
-
Rodman & Renshaw Starts FibroBiologics (FBLG) at Buy

